Skip to main content
Top
Published in: Tumor Biology 3/2013

01-06-2013 | Research Article

miR-214 promotes tumorigenesis by targeting lactotransferrin in nasopharyngeal carcinoma

Authors: Min Deng, Qiurong Ye, Zailong Qin, Ying Zheng, Wei He, Hailin Tang, Yanhong Zhou, Wei Xiong, Ming Zhou, Xiaoling Li, Qun Yan, Jian Ma, Guiyuan Li

Published in: Tumor Biology | Issue 3/2013

Login to get access

Abstract

LTF (lactotransferrin, or lactoferrin) plays important role in innate immunity, and its anti-tumor function has also been reported in multiple cancers. We previously reported that LTF is significantly down-regulated in nasopharyngeal carcinoma (NPC) and acts as a tumor suppressor by suppressing AKT signaling. However, the exact mechanism of the down-regulation of LTF in NPC has not been revealed. In the current study, we screened and identified LTF is a bona fide target of miR-214 in NPC cells. miR-214 mimics significantly suppressed LTF mRNA and protein expression levels in NPC cells. miR-214 not only can promote NPC cell proliferation and invasion abilities in vitro, but also can accelerate tumor formation and lung metastasis in a mouse xenograft model. The pro-tumor function of miR-214 was depended on LTF suppression since LTF re-expression can reverse it. miR-214 can also activate AKT signaling by suppressing LTF expression. Furthermore, miR-214 expression level was up-regulated in NPC especially in metastasis-prone NPC tumor tissues compared with normal nasopharyngeal epithelial tissues, while the LTF expression level was negatively correlated with miR-214, suggesting that miR-214 targeting is partly responsible for LTF down-regulation in NPC specimens.
Appendix
Available only for authorised users
Literature
1.
go back to reference Legrand D. Lactoferrin, a key molecule in immune and inflammatory processes. Biochem Cell Biol. 2012;90(3):252–68.PubMedCrossRef Legrand D. Lactoferrin, a key molecule in immune and inflammatory processes. Biochem Cell Biol. 2012;90(3):252–68.PubMedCrossRef
2.
go back to reference Legrand D, Pierce A, Elass E, Carpentier M, Mariller C, et al. Lactoferrin structure and functions. Adv Exp Med Biol. 2008;606:163–94.PubMedCrossRef Legrand D, Pierce A, Elass E, Carpentier M, Mariller C, et al. Lactoferrin structure and functions. Adv Exp Med Biol. 2008;606:163–94.PubMedCrossRef
3.
go back to reference Alexander DB, Iigo M, Yamauchi K, Suzui M, Tsuda H. Lactoferrin: an alternative view of its role in human biological fluids. Biochem Cell Biol. 2012;90(3):279–306.PubMedCrossRef Alexander DB, Iigo M, Yamauchi K, Suzui M, Tsuda H. Lactoferrin: an alternative view of its role in human biological fluids. Biochem Cell Biol. 2012;90(3):279–306.PubMedCrossRef
4.
go back to reference Bezault J, Bhimani R, Wiprovnick J, Furmanski P. Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res. 1994;54(9):2310–2.PubMed Bezault J, Bhimani R, Wiprovnick J, Furmanski P. Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res. 1994;54(9):2310–2.PubMed
5.
go back to reference Li WY, Li QW, Han ZS, Jiang ZL, Yang H, et al. Growth suppression effects of recombinant adenovirus expressing human lactoferrin on cervical cancer in vitro and in vivo. Cancer Biother Radiopharm. 2011;26(4):477–83.PubMedCrossRef Li WY, Li QW, Han ZS, Jiang ZL, Yang H, et al. Growth suppression effects of recombinant adenovirus expressing human lactoferrin on cervical cancer in vitro and in vivo. Cancer Biother Radiopharm. 2011;26(4):477–83.PubMedCrossRef
6.
go back to reference Matsuda Y, Saoo K, Hosokawa K, Yamakawa K, Yokohira M, et al. Post-initiation chemopreventive effects of dietary bovine lactoferrin on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in female A/J mice. Cancer Lett. 2007;246(1–2):41–6.PubMedCrossRef Matsuda Y, Saoo K, Hosokawa K, Yamakawa K, Yokohira M, et al. Post-initiation chemopreventive effects of dietary bovine lactoferrin on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in female A/J mice. Cancer Lett. 2007;246(1–2):41–6.PubMedCrossRef
7.
go back to reference Sekine K, Watanabe E, Nakamura J, Takasuka N, Kim DJ, et al. Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats. Jpn J Cancer Res. 1997;88(6):523–6.PubMedCrossRef Sekine K, Watanabe E, Nakamura J, Takasuka N, Kim DJ, et al. Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats. Jpn J Cancer Res. 1997;88(6):523–6.PubMedCrossRef
8.
go back to reference Tsuda H, Sekine K, Nakamura J, Ushida Y, Kuhara T, et al. Inhibition of azoxymethane initiated colon tumor and aberrant crypt foci development by bovine lactoferrin administration in F344 rats. Adv Exp Med Biol. 1998;443:273–84.PubMed Tsuda H, Sekine K, Nakamura J, Ushida Y, Kuhara T, et al. Inhibition of azoxymethane initiated colon tumor and aberrant crypt foci development by bovine lactoferrin administration in F344 rats. Adv Exp Med Biol. 1998;443:273–84.PubMed
9.
go back to reference Varadhachary A, Wolf JS, Petrak K, O'Malley Jr BW, Spadaro M, et al. Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int J Cancer. 2004;111(3):398–403.PubMedCrossRef Varadhachary A, Wolf JS, Petrak K, O'Malley Jr BW, Spadaro M, et al. Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int J Cancer. 2004;111(3):398–403.PubMedCrossRef
10.
go back to reference Tuccari G, Barresi G. Lactoferrin in human tumours: immunohistochemical investigations during more than 25 years. Biometals. 2011;24(5):775–84.PubMedCrossRef Tuccari G, Barresi G. Lactoferrin in human tumours: immunohistochemical investigations during more than 25 years. Biometals. 2011;24(5):775–84.PubMedCrossRef
11.
go back to reference Zhou Y, Zeng Z, Zhang W, Xiong W, Wu M, et al. Lactotransferrin: a candidate tumor suppressor-deficient expression in human nasopharyngeal carcinoma and inhibition of NPC cell proliferation by modulating the mitogen-activated protein kinase pathway. Int J Cancer. 2008;123(9):2065–72.PubMedCrossRef Zhou Y, Zeng Z, Zhang W, Xiong W, Wu M, et al. Lactotransferrin: a candidate tumor suppressor-deficient expression in human nasopharyngeal carcinoma and inhibition of NPC cell proliferation by modulating the mitogen-activated protein kinase pathway. Int J Cancer. 2008;123(9):2065–72.PubMedCrossRef
12.
go back to reference Deng M, Zhang W, Tang H, Ye Q, Liao Q, et al. Lactotransferrin acts as a tumor suppressor in nasopharyngeal carcinoma by repressing AKT through multiple mechanisms. Oncogene. 2012. doi:10.1038/onc.2012.434. Epub ahead of print. Deng M, Zhang W, Tang H, Ye Q, Liao Q, et al. Lactotransferrin acts as a tumor suppressor in nasopharyngeal carcinoma by repressing AKT through multiple mechanisms. Oncogene. 2012. doi:10.​1038/​onc.​2012.​434. Epub ahead of print.
13.
go back to reference Deng L, Jing N, Tan G, Zhou M, Zhan F, et al. A common region of allelic loss on chromosome region 3p25.3–26.3 in nasopharyngeal carcinoma. Genes Chromosomes Cancer. 1998;23(1):21–5.PubMedCrossRef Deng L, Jing N, Tan G, Zhou M, Zhan F, et al. A common region of allelic loss on chromosome region 3p25.3–26.3 in nasopharyngeal carcinoma. Genes Chromosomes Cancer. 1998;23(1):21–5.PubMedCrossRef
14.
go back to reference Xiong W, Zeng ZY, Xia JH, Xia K, Shen SR, et al. A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res. 2004;64(6):1972–4.PubMedCrossRef Xiong W, Zeng ZY, Xia JH, Xia K, Shen SR, et al. A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res. 2004;64(6):1972–4.PubMedCrossRef
15.
go back to reference Yi HM, Li H, Peng D, Zhang HJ, Wang L, et al. Genetic and epigenetic alterations of LTF at 3p21.3 in nasopharyngeal carcinoma. Oncol Res. 2006;16(6):261–72.PubMed Yi HM, Li H, Peng D, Zhang HJ, Wang L, et al. Genetic and epigenetic alterations of LTF at 3p21.3 in nasopharyngeal carcinoma. Oncol Res. 2006;16(6):261–72.PubMed
16.
go back to reference Zhang H, Feng X, Liu W, Jiang X, Shan W, et al. Underlying mechanisms for LTF inactivation and its functional analysis in nasopharyngeal carcinoma cell lines. J Cell Biochem. 2011;112(7):1832–43.PubMedCrossRef Zhang H, Feng X, Liu W, Jiang X, Shan W, et al. Underlying mechanisms for LTF inactivation and its functional analysis in nasopharyngeal carcinoma cell lines. J Cell Biochem. 2011;112(7):1832–43.PubMedCrossRef
18.
go back to reference Mao YP, Li WF, Chen L, Sun Y, Liu LZ, et al. A clinical verification of the Chinese 2008 staging system for nasopharyngeal carcinoma. Ai Zheng. 2009;28(10):1022–8.PubMed Mao YP, Li WF, Chen L, Sun Y, Liu LZ, et al. A clinical verification of the Chinese 2008 staging system for nasopharyngeal carcinoma. Ai Zheng. 2009;28(10):1022–8.PubMed
19.
go back to reference Sun Y, Ma J. Comment for the Chinese 2008 staging system for nasopharyngeal carcinoma. Ai Zheng. 2009;28(10):1016–21.PubMed Sun Y, Ma J. Comment for the Chinese 2008 staging system for nasopharyngeal carcinoma. Ai Zheng. 2009;28(10):1016–21.PubMed
20.
go back to reference Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45.PubMedCrossRef Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45.PubMedCrossRef
21.
go back to reference Liao Y, Du X, Lonnerdal B. miR-214 regulates lactoferrin expression and pro-apoptotic function in mammary epithelial cells. J Nutr. 2010;140(9):1552–6.PubMedCrossRef Liao Y, Du X, Lonnerdal B. miR-214 regulates lactoferrin expression and pro-apoptotic function in mammary epithelial cells. J Nutr. 2010;140(9):1552–6.PubMedCrossRef
22.
go back to reference Teng C, Gladwell W, Raphiou I, Liu E. Methylation and expression of the lactoferrin gene in human tissues and cancer cells. Biometals. 2004;17(3):317–23.PubMedCrossRef Teng C, Gladwell W, Raphiou I, Liu E. Methylation and expression of the lactoferrin gene in human tissues and cancer cells. Biometals. 2004;17(3):317–23.PubMedCrossRef
23.
go back to reference Lu M, Zhang Q, Deng M, Miao J, Guo Y, et al. An analysis of human microRNA and disease associations. PLoS One. 2008;3(10):e3420.PubMedCrossRef Lu M, Zhang Q, Deng M, Miao J, Guo Y, et al. An analysis of human microRNA and disease associations. PLoS One. 2008;3(10):e3420.PubMedCrossRef
24.
go back to reference Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, et al. MicroRNA expression profiling in human ovarian cancer: Mir-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68:425–33.PubMedCrossRef Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, et al. MicroRNA expression profiling in human ovarian cancer: Mir-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68:425–33.PubMedCrossRef
25.
go back to reference Kanaan Z, Rai SN, Eichenberger MR, Barnes C, Dworkin AM, et al. Differential microRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer. Hum Mutat. 2012;33(3):551–60.PubMedCrossRef Kanaan Z, Rai SN, Eichenberger MR, Barnes C, Dworkin AM, et al. Differential microRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer. Hum Mutat. 2012;33(3):551–60.PubMedCrossRef
26.
go back to reference Vergoulis T, Vlachos IS, Alexiou P, Georgakilas G, Maragkakis M, et al. TarBase 6.0: capturing the exponential growth of miRNA targets with experimental support. Nucleic Acids Res. 2012;40:D222–9. Database issue.PubMedCrossRef Vergoulis T, Vlachos IS, Alexiou P, Georgakilas G, Maragkakis M, et al. TarBase 6.0: capturing the exponential growth of miRNA targets with experimental support. Nucleic Acids Res. 2012;40:D222–9. Database issue.PubMedCrossRef
27.
go back to reference Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, et al. microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J. 2011;30(10):1990–2007.PubMedCrossRef Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, et al. microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J. 2011;30(10):1990–2007.PubMedCrossRef
28.
go back to reference Yang Z, Chen S, Luan X, Li Y, Liu M, et al. MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. IUBMB Life. 2009;61(11):1075–82.PubMedCrossRef Yang Z, Chen S, Luan X, Li Y, Liu M, et al. MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. IUBMB Life. 2009;61(11):1075–82.PubMedCrossRef
Metadata
Title
miR-214 promotes tumorigenesis by targeting lactotransferrin in nasopharyngeal carcinoma
Authors
Min Deng
Qiurong Ye
Zailong Qin
Ying Zheng
Wei He
Hailin Tang
Yanhong Zhou
Wei Xiong
Ming Zhou
Xiaoling Li
Qun Yan
Jian Ma
Guiyuan Li
Publication date
01-06-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0718-y

Other articles of this Issue 3/2013

Tumor Biology 3/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine